The performance of e23(Fv)PEs, recombinant toxins targeting the erbB-2 protein.
The overexpression of the erbB-2 (HER-2, neu) gene has attracted significant interest as a molecular target for the rational design of cancer therapies. This review examines the design and preclinical testing phase for one such experimental therapy, recombinant toxins targeted to the erbB-2 protein, termed e23(Fv)PEs.
King
C R
CR
Lombardi Cancer Center, Georgetown University Medical Center, Georgetown University, Washington DC 20007-2197, USA.
Fischer
P H
PH
Rando
R F
RF
Pastan
I
I
D036002:ADP Ribose Transferases; D000818:Animals; D000906:Antibodies; D000917:Antibody Formation; D001427:Bacterial Toxins / Q000235:genetics; D004353:Drug Evaluation, Preclinical; D005098:Exotoxins / Q000494:pharmacology; D006801:Humans; D000922:Immunotoxins / Q000008:administration & dosage / Q000276:immunology / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D008252:Macaca fascicularis; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000235:genetics; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000187:drug effects* / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D057127:Single-Chain Antibodies; D014407:Tumor Cells, Cultured; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A
D036002:ADP Ribose Transferases; D000906:Antibodies; D001427:Bacterial Toxins; D005098:Exotoxins; D000922:Immunotoxins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins; D057127:Single-Chain Antibodies; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A; C089922:OLX 209